The NM_000203.5:c.1487C>T variant in IDUA is a missense variant predicted to cause substitution of proline by leucine at amino acid 496, p.(Pro496Leu). This variant has been reported to account for 0.65% of disease-causing alleles in individuals with MPS I (PMIDs: 28752568, 7550232, 18463126). At least two probands have been reported to be compound heterozygous, phase not confirmed, for the variant and another variant in IDUA that has been classified as pathogenic by the ClinGen LD VCEP, c.1205G>A (p.Trp402Ter) (PMID:18463126, 28752568). Another patient has been reported who is compound heterozygous for the variant and c.223G>A (p.Ala75Thr) (PMID: 7550232). The allelic data for this patient will be used in the classification of p.Ala75Thr and is not included here to avoid circular logic (PM3 applied; insufficient evidence to apply PP4). The highest population minor allele frequency in gnomAD v4.1.0. is 0.000012 (1/80558 alleles) in the South Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.00025), meeting this criterion (PM2_Supporting). When the variant was expressed in Cos-1 cells, IDUA activity was absent (PMID: 7550232) (PS3_Supporting). Computational predictor tools (REVEL score 0.647) suggest that this variant may be deleterious to IDUA function (PP3). In addition, a different missense variant, c.1487C>G (p.Pro496Arg) [ClinVar Variation ID 496861] in the same codon has been classified as likely pathogenic for MPS I by the ClinGen LD VCEP (PM5_Supporting). There is a ClinVar entry for this variant (Variation ID: 551675). In summary, this variant meets the criteria to be classified as likely pathogenic for MPS I based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 1.0.0): PS3_Supporting, PM2_Supporting, PM3, PM5_Supporting, PP3. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 6, 2024)